Skip to main content

Table 1 Basic demographic and clinical information of patients with PPIs -associated SIADH (January 2004 to March 2020)

From: Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study

Characteristics

Reports,no(%)

Reporting region

 Europe

222 (81.3)

 Asian

24 (8.8)

 North America

18 (6.6)

 Oceania

2 (0.7)

 Unspecified

7 (2.6)

Reporters

 Healthcare professionals

234 (85.7)

 Non-healthcare professionals

13 (4.8)

 Unspecified

26 (9.5)

Reporting year

 2019

72 (26.4)

 2018

33 (12.1)

 2017

32 (11.7)

 2016

20 (7.3)

 2015

24 (8.8)

 2014

13 (4.8)

 2013

11 (4.0)

 2012

11 (4.0)

 2011

27 (9.9)

 2010

7 (2.6)

 2009

4 (1.5)

 2008

3 (1.1)

 2007

3 (1.1)

 2006

4 (1.5)

 2005

6 (2.2)

 2004

3 (1.1)

Sex of patients

 Male

114 (48.7)

 Female

133 (41.8)

 Unknown or missing

26 (9.5)

Age groups (years)

 <18

2 (0.7)

 18–44

4 (1.5)

 45–64

28 (10.3)

 65–74

71 (26.0)

 75–84

82 (30.0)

  ≥ 85

41 (15.0)

 Unknown or missing

45 (16.5)

PPIs as suspected drugs

 Omeprazole

122 (44.7)

 Lansoprazole

43 (15.8)

 Pantoprazole

64 (23.4)

 Rabeprazole

10 (3.7)

 Esomeprazole

34 (12.5)

 Dexlansoprazole

0 (0.0)

Indications for tumors of different sites

 Gastroesophageal reflux disease

37 (17.1)

 Peptic ulcer disease

14 (6.5)

 Gastroduodenitis

10 (4.6)

 Functional dyspepsia

9 (4.2)

 Epigastric pain or discomfort

7 (3.2)

 Non-specified gastrointestinal disorders

4 (1.9)

 Eradication of Helicobacter pylori infection

4 (1.9)

 Peptic ulcer-related gastrointestinal bleeding

2 (0.9)

 Lower abdominal discomfort

2 (0.9)

 Esophagitis

1 (0.5)

 Other indications

28 (13.0)

 Unknown or missing indications

98 (45.4)

  1. PPIs Proton pump inhibitors, SIADH Inappropriate secretion of antidiuretic hormone